MPH Health Care AG

XTRA:93M1 Stock Report

Market Cap: €105.3m

MPH Health Care Valuation

Is 93M1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 93M1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 93M1 (€24.4) is trading below our estimate of fair value (€593.77)

Significantly Below Fair Value: 93M1 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 93M1?

Key metric: As 93M1 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 93M1. This is calculated by dividing 93M1's market cap by their current earnings.
What is 93M1's PE Ratio?
PE Ratio0.9x
Earnings€119.48m
Market Cap€105.32m

Price to Earnings Ratio vs Peers

How does 93M1's PE Ratio compare to its peers?

The above table shows the PE ratio for 93M1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average20.1x
2FJ0 Pierrel
29.9xn/a€92.8m
PSG PharmaSGP Holding
15.4x13.9%€280.6m
DMP Dermapharm Holding
22.3x18.1%€2.0b
2INV 2invest
12.7xn/a€63.8m
93M1 MPH Health Care
0.9x-65.7%€105.3m

Price-To-Earnings vs Peers: 93M1 is good value based on its Price-To-Earnings Ratio (0.9x) compared to the peer average (20.1x).

Price to Earnings Ratio vs Industry

How does 93M1's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.20.3x21.6%
93M1 MPH Health Care
 0.9x-65.7%US$109.68m
93M1 0.9xIndustry Avg. 20.3xNo. of Companies10PE01632486480+
2 CompaniesEstimated GrowthMarket Cap
Industry Avg.20.3x21.6%
93M1 MPH Health Care
 0.9x-65.7%US$109.68m
No more companies

Price-To-Earnings vs Industry: 93M1 is good value based on its Price-To-Earnings Ratio (0.9x) compared to the European Pharmaceuticals industry average (20.3x).

Price to Earnings Ratio vs Fair Ratio

What is 93M1's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

93M1 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio0.9x
Fair PE Ratio3.3x

Price-To-Earnings vs Fair Ratio: 93M1 is good value based on its Price-To-Earnings Ratio (0.9x) compared to the estimated Fair Price-To-Earnings Ratio (3.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Aspen Pharmacare Holdings

R75.5b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R8.95

7D

0.6%

1Y

4.7%

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.70

7D

-4.3%

1Y

91.5%

Almirall

€1.8b

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

E2Z

€8.29

7D

-1.8%

1Y

0.2%